| Autor: |
DE Luca L; Division of Cardiology, Department of Cardio-Thoraco-Vascular Sciences, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy - l.deluca@smatteo.pv.it., Crispino SP; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy., Andreoli F; Department of Clinical and Molecular Medicine, Sapienza University, Rome, Italy., DI Fusco SA; Clinical and Rehabilitation Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy., Pannone A; Division of Vascular Surgery, Department of Cardio-Thoraco-Vascular Sciences, A.O. San Camillo-Forlanini Hospital, Rome, Italy., Nusca A; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy., Colivicchi F; Clinical and Rehabilitation Unit, San Filippo Neri Hospital, ASL Roma 1, Rome, Italy., Grigioni F; Department of Cardiovascular Sciences, Fondazione Policlinico Universitario Campus Bio-Medico, Rome, Italy., Gabrielli D; Division of Cardiology, Department of Cardio-Thoraco-Vascular Sciences, A.O. San Camillo-Forlanini, Rome, Italy. |
| Abstrakt: |
Cardiovascular diseases (CVD) remain the leading cause of mortality globally and require innovative strategies for effective prevention and treatment. The polypill concept, which integrates multiple cardioprotective agents into a single dosage form, has emerged as a promising approach to improve adherence and simplify the management of cardiovascular risk factors. We review clinical trials and observational studies evaluating the impact of the polypill on reducing the incidence of major cardiovascular events (MACEs), its influence on medication adherence, and its potential to fill treatment gaps in diverse populations. Also of note are the pharmacoeconomic implications of the widespread use of the polypill, particularly in low- and middle-income countries where the burden of cardiovascular disease is increasing. Although the polypill demonstrates a favorable profile in improving therapeutic compliance and reducing cardiovascular risk factors, debates persist regarding its efficacy compared to individualized treatment regimens. This review summarizes the current evidence on the efficacy, safety, and cost-effectiveness of the polypill in CVD primary and secondary prevention. Furthermore, potential challenges in implementing the polypill strategy include tailoring the components to patient-specific risk profiles and the need for robust evidence from large-scale randomized controlled trials to substantiate its long-term benefits. |
